Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Vigonvita Life Sciences Co., Ltd.
蘇州旺山旺水生物醫藥股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2630)

VOLUNTARY ANNOUNCEMENT
(1) THE NEW DRUG APPLICATION (NDA) FOR 昂偉達® SEMENAFIL HYDROCHLORIDE TABLETS HAS BEEN ACCEPTED BY THE DEPARTMENT OF HEALTH OF HONG KONG, CHINA AND THE PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAO, CHINA; AND
(2) CLARIFICATION ANNOUNCEMENT IN RELATION TO THE INTERIM REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2026

I. THE NEW DRUG APPLICATION (NDA) FOR 昂偉達® SEMENAFIL HYDROCHLORIDE TABLETS HAS BEEN ACCEPTED BY THE DEPARTMENT OF HEALTH OF HONG KONG, CHINA AND THE PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAO, CHINA

This announcement is made by Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司) (the "**Company**", together with its subsidiaries, collectively the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors of the latest business development of the Company.

A. Introduction

The board of directors of the Company (the "**Board**") is pleased to announce that recently, the new drug application ("**NDA**") in the Hong Kong Special Administrative Region of China (the "**Hong Kong**") for the indication of erectile dysfunction ("**ED**") of Semenafil Hydrochloride Tablets (brand name: 昂偉達®, R&D code: TPN171), a Class 1 new drug self-developed by the Group, has been officially accepted by the Department of Health of Hong Kong; and the NDA in the Macao Special Administrative Region of China was also officially accepted by the Pharmaceutical Administration Bureau on September 30, 2026.

B. Background and Basis of Application

The NDA is primarily based on a multicenter, randomized, double-blind, parallel placebo-controlled Phase III clinical study (NCT05188989) of TPN171 for the indication of erectile dysfunction. The study results demonstrated that TPN171 exhibited significant clinical efficacy with a favorable safety profile.

C. About TPN171

TPN171 is a highly active and highly selective type-5 phosphodiesterase (PDE5) inhibitor with a novel chemical structure. The clinical study results for its ED indication demonstrated rapid onset of action, an appropriate duration of efficacy, a favorable safety profile, a wide range of patient populations and diverse applications, indicating its potential to become a best-in-class drug.

TPN171 for its indication of ED has been approved for marketing in China (brand name: 昂偉達®) and Uzbekistan (brand name: Onvita®), respectively. In September 2026, the clinical trial application for TPN171 for the indication of Alzheimer's disease was approved by the National Medical Products Administration of China.

II. CLARIFICATION ANNOUNCEMENT IN RELATION TO THE INTERIM REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2026

Reference is made to the interim report of the Company for the six months ended June 30, 2026 (the "**Interim Report**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Interim Report. In the section headed "Future Plan for Significant Investments or Capital Assets – fund investment portfolio" on pages 17 to 18 of the Interim Report, it was disclosed that the wealth management products subscribed for by the Company were managed by Capital Group and Prudent Wealth, respectively. The Board wishes to clarify that, as the relevant subscription agreements entered into with Capital Group and Prudent Wealth did not specify the managers of such products, the Company had understood at the time of the Interim Report that such products were managed by Capital Group and Prudent Wealth themselves. Based on the subsequent communications with Capital Group and Prudent Wealth, the fund manager of the product subscribed for from Capital Group is Beta International Securities Limited, and the investment manager of the product subscribed for from Prudent Wealth is Infinite Capital Limited, with Smart Rise Advisory Limited acting as its fund administrator. Save as disclosed above, all other information in the Interim Report remains unchanged.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.